88069-49-2

Basic information

• Product Name: Pilsicainide hydrochloride
• Synonyms: Pilzicainide hydrochloride;Rizumcote;Tatsupilljin;Pilsicainide-Hydrochlordie;N-(2,6-Dimethylphenyl)-2-(hexahydro-1H-pyrrolizin-7a-yl)acetamide hydrochloride;n-(2,6-dimethylphenyl)-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-yl)acetamide hydrochloride;PILSICAINIDE HYDROCHLORIDE;PILSICAINIDE HYDROCHLORIDE HEMIHYDRATE
• CAS NO: 88069-49-2
• Molecular Formula: C₁₇H₂₄N₂O*ClH
• Molecular Weight: 272.39
• Mol File: 88069-49-2.mol
• Article Data: 2

Chemical Properties

• Melting Point: 212-214°
• Boiling Point: 416.9 °C at 760 mmHg
• Flash Point: 205.9 °C
• Appearance: /
• Vapor Pressure: 3.7E-07mmHg at 25°C
• Storage Temp.: room temp
• Solubility: Chloroform (Slightly), Water (Slightly)
• CAS DataBase Reference: Pilsicainide hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: Pilsicainide hydrochloride(88069-49-2)
• EPA Substance Registry System: Pilsicainide hydrochloride(88069-49-2)

Safety Data

• RIDADR: UN 2811 6.1 / PGIII
• WGK Germany: 3
• Hazardous Substances Data: 88069-49-2(Hazardous Substances Data)

Usage

Description

Pilsicainide hydrochloride is a pyrrolidine lidocaine derivative with antiarrhythmic activity. It is the first pharmaceutical product introduced by Suntory and was solely developed in Japan. Pilsicainide hydrochloride is reported to be highly effective in the treatment of premature ventricular contraction. It has no anticholinergic or CNS activity and is not as likely as other class 1C antiarrhythmics to have restricted indications. It is also known by the brand name Sunrhythm.

Uses

Used in Cardiology:
Pilsicainide hydrochloride is used as a sodium channel blocker for the treatment of premature ventricular contraction. It is effective in managing arrhythmias and has been studied for its effects on electrophysiological parameters in guinea pig pulmonary vein preparation, its effects on Ca2+ release and arrhythmic events in Andersen-Tawil syndrome induced pluripotent stem cells (ATS-iPSC)-derived cardiomyocytes, and its electrophysiological effects on the guinea pig atrium.

Biochem/physiol Actions

Pilsicainide hydrochloride is a pure sodium channel blocker and an open channel blocker of Na+1 channels. Pilsicainide was defined as a pure sodium channel blocker. The compound is classified as a class Ic antiarrhythmic drug, and was originally developed in Japan. Similar to Lidocaine, Pilsicainide binds to open channels, but slowly. Pilsicainide is capable of selectively blocking the late currents in the mutant Na(+) channels that show dominant abnormal burst openings such as in δKPQ mutants. The compound is used to induce Brugada syndrome (BS) in animal models.

InChI:InChI=1/C17H24N2O.ClH.H2O/c1-13-6-3-7-14(2)16(13)18-15(20)12-17-8-4-10-19(17)11-5-9-17;;/h3,6-7H,4-5,8-12H2,1-2H3,(H,18,20);1H;1H2

Upstream product

• 87-62-7 2,6-dimethylaniline 
• 53984-98-8 2-cyano-N-(2,6-dimethyl-phenyl)-acetamide 
• 15960-82-4 ethyl 3-((2,6-dimethylphenyl)amino)-3-oxopropanoate 

Downstream Products

• 100446-01-3 3-aminopilsicainide 
• 100446-00-2 N-(2,6-dimethyl-3-nitrophenyl)-2-(hexahydropyrrolizin-7a-yl)acetamide 

Relevant articles and documents

Method of Manufacturing Pyrrolizidine Compound And Method of Manufacturing Pyrrolizidine Hydrochloride Hemihydrate

The present invention relates to a method for manufacturing a pyrrolizidine compound and a method for manufacturing pyrrolizidine hydrochloride hemihydrate. According to the present invention, by including the reaction using phosphoryl chloride (POCl_3) and pyridine, and also aniline intermediates, it is possible to provide effects of lowering the manufacturing cost of the pyrrolizidine compound and pyrrolizidine hydrochloride hemihydrate, solving the manufacturing environmental problem, and at the same time, increasing a manufacturing yield.